Zhou Y, et al. - The link between sirtuin 3 (SIRT3) expression and prognosis in various cancers was studied using data from all relevant studies from PubMed, Embase, Web of Science and the Cochrane Library. SIRT3 was found to be associated with the overall survival (OS) in specific cancers. In breast cancer (BC), colon cancer (CC) and non-small-cell lung cancer (NSCLC), SIRT3 was recognized as an unfavorable prognostic factor. However, SIRT3 was shown to be a favorable prognostic factor in chronic lymphocytic leukemia (CLL), hepatocellular carcinoma (HCC), pancreatic carcinoma (PC) and renal cell carcinoma (RCC), but especially in HCC.

Methods

• All the relevant studies were identified from PubMed, Embase, Web of Science and the Cochrane Library retrieval by the end of September 29, 2017.
• Studies meeting the inclusion criteria were included in the meta-analysis.

Results

• Overall, 17 studies involving 2,865 patients were included.
• SIRT3 expression was not found to be significantly related to overall survival (OS) (hazard ratio [HR]=0.87, 95% CI=0.59–1.29, P=0.50) and disease-free survival (HR=0.87, 95% CI=0.57–1.31, P=0.50) in total various cancers.
• Researchers found significant link between SIRT3 expression and OS in specific cancers, including CLL (HR=0.48, 95% CI=0.26–0.89, P=0.019), HCC (HR=0.56, 95% CI=0.42–0.74, P<0.001), PC (HR=0.55, 95% CI=0.30–1.00, P=0.049), RCC (HR=0.13, 95% CI=0.02–0.98, P=0.048), BC (HR=2.53, 95% CI=1.83–3.67, P<0.001), CC (HR=1.87, 95% CI=1.12–3.26, P=0.022) NSCLC (HR=2.20, 95% CI=1.38–3.50, P=0.001).
• SIRT3 expression was related to tumor size (odds ratio [OR]=1.41, 95% CI=1.02–1.94, P=0.04), tumor differentiation (OR=1.52, 95% CI=1.08–2.16, P=0.02) and clinical stage (OR=2.07, 95% CI=1.23–3.46, P=0.01) in HCC.